Ni Shuang-Shuang, Zhang Ji, Zhao Wei-Li, Dong Xiao-Chun, Wang Jin-Lin
Department of Radiology, Changzheng Hospital, Second Military Medical University, No. 415, Fengyang Road, Shanghai, 200003, China.
Tumour Biol. 2013 Jun;34(3):1813-8. doi: 10.1007/s13277-013-0721-3. Epub 2013 Mar 9.
The purpose of this study was to assess ADAM17 expression and to explore its contribution to the non-small cell lung cancer (NSCLC). Real-time quantitative reverse transcriptase-polymerase chain reaction was conducted to detect ADAM17 mRNA expression. In addition, ADAM17 expression was analyzed by immunohistochemistry in 124 clinicopathologically characterized NSCLC cases. The correlation of ADAM17 expression with patients' survival rate was assessed by Kaplan-Meier and Cox regression. The expression levels of ADAM17 mRNA and protein in NSCLC tissues were both significantly higher than those in non-cancerous tissues. In addition, high expression of ADAM17 was significantly correlated with tumor grade (P=0.026), tumor size (P=0.001), clinical stage (P=0.016), and lymph node metastases (P<0.001). Furthermore, multivariate analysis suggested that tumor grade, tumor size, clinical stage, lymph node metastases, and ADAM17 expression were independent prognostic indicators for NSCLC. Our data suggest for the first time that the increased expression of ADAM17 in NSCLC is associated significantly with aggressive progression and poor prognosis. ADAM17 may be an important molecular marker for predicting the carcinogenesis, progression, and prognosis of NSCLC.
本研究的目的是评估ADAM17的表达，并探讨其在非小细胞肺癌（NSCLC）中的作用。采用实时定量逆转录聚合酶链反应检测ADAM17 mRNA表达。此外，通过免疫组织化学分析了124例具有临床病理特征的NSCLC病例中ADAM17的表达。采用Kaplan-Meier法和Cox回归评估ADAM17表达与患者生存率的相关性。NSCLC组织中ADAM17 mRNA和蛋白的表达水平均显著高于癌旁组织。此外，ADAM17的高表达与肿瘤分级（P = 0.026）、肿瘤大小（P = 0.001）、临床分期（P = 0.016）和淋巴结转移（P < 0.001）显著相关。此外，多因素分析表明，肿瘤分级、肿瘤大小、临床分期、淋巴结转移和ADAM17表达是NSCLC的独立预后指标。我们的数据首次表明，NSCLC中ADAM17表达的增加与侵袭性进展和不良预后显著相关。ADAM17可能是预测NSCLC发生、发展和预后的重要分子标志物。
